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Abstract: The p53 protein plays a major role in cancer pre-
vention, and over 50% of cancer diagnoses can be attribut-
ed to p53 malfunction. The common p53 mutation Y220C
causes local protein unfolding, aggregation, and can result
in a loss of Zn in the DNA-binding domain. Structural analy-
sis has shown that this mutant creates a surface site that
can be stabilized using small molecules, and herein a multi-
functional approach to restore function to p53-Y220C is re-
ported. A series of compounds has been designed that con-
tain iodinated phenols aimed for interaction and stabiliza-
tion of the p53-Y220C surface cavity, and Zn-binding frag-
ments for metallochaperone activity. Their Zn-binding affini-
ty was characterized using spectroscopic methods and
demonstrate the ability of compounds L4 and L5 to increase
intracellular levels of Zn2+ in a p53-Y220C-mutant cell line.
The in vitro cytotoxicity of our compounds was initially
screened by the National Cancer Institute (NCI-60), followed
by testing in three stomach cancer cell lines with varying
p53 status’, including AGS (WTp53), MKN1 (V143A), and
NUGC3 (Y220C). Our most promising ligand, L5, is nearly 3-
fold more cytotoxic than cisplatin in a large number of cell
lines. The impressive cytotoxicity of L5 is further maintained
in a NUGC3 3D spheroid model. L5 also induces Y220C-spe-
cific apoptosis in a cleaved caspase-3 assay, reduces levels of
unfolded mutant p53, and recovers p53 transcriptional func-
tion in the NUGC3 cell line. These results show that these
multifunctional scaffolds have the potential to restore wild-
type function in mutant p53-Y220C.
Introduction
The p53 protein, referred to as the “guardian of the human
genome,”[1] is a tetrameric transcription factor that regulates
the expression of target genes to induce antiproliferative cellu-
lar responses.[2] Among those genes are those that initiate
apoptosis, DNA repair, and cell cycle arrest of damaged cells.[3]
However, in over 50% of cancer diagnoses, p53 does not carry
out its essential function.[4] The most common alterations to
p53 are point mutations that affect tertiary structure or alter
the protein’s ability to bind DNA.[5] The net result is that cells
bearing malfunctioning p53 are susceptible to enhanced prolif-
eration and survival.[6] There is significant therapeutic potential
for p53, and pharmacological restoration of function to mutant
p53 is an acknowledged chemotherapeutic target.[7] Herein, we
describe the synthesis, characterization, and in vitro testing of
a new series of bifunctional ligands designed to restore func-
tion in mutant p53, specifically the Y220C point mutation.
The majority of p53 mutations are point mutations localized
to the protein’s core DNA-binding (p53C) domain,[6] and a
number of small molecules have been developed in an effort
to reactivate mutant p53.[8] One such example is APR-246
(Scheme 1a), which has shown positive results in a Phase I/II
clinical trial.[9] APR-246 is a pro-drug and is activated to a Mi-
chael acceptor that binds covalently to cysteine residues of
Scheme 1. Chemical structures of (a) APR-246 (PRIMA-1MET) (b) NSC319726
(ZMC1) (c) PhiKan083 and (d) iodinated phenol small molecule shown to
bind the p53 Y220C mutant pocket.
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mutant p53, resulting in protein reactivation.[10] Due to the
non-specific nature of this process, APR-246 also binds other
proteins, and modification of thioredoxin reductase 1 leads to
increased reactive oxygen species (ROS) production, an addi-
tional cytotoxic mechanism.[11]
The p53C domain contains a single Zn2+ ion that is required
for proper protein folding and function.[12] Mutations to p53C
can disrupt protein stability and/or cause loss of Zn.[13] Conse-
quently, the discovery of small molecule Zn chaperones aimed
to restore wild-type function in mutant p53 has generated
much attention.[8c, 14] For example, the thiosemicarbazone
ligand ZMC1 (Scheme 1b) induces conformational “wild-type-
like” change in the common Zn-binding p53 mutation
(R175H), and restores p53 transactivation function.[14] Further
studies indicate that subtle tuning of the Zn-binding affinity of
the metallochaperones is critical for p53 reactivation,[15] as it
functions by repopulating Zn-deficient p53C with Zn2+ .[16]
More broadly, targeted metal ion chelation and redistribution
has been shown as a promising anti-cancer strategy,[17] and a
number of recent studies have highlighted both the novelty
and complexity of this approach.[8c, 18]
Mutations to the p53C domain can result in structural desta-
bilization such that the protein unfolds at or below physiologi-
cal temperatures.[3a] The Y220C point mutation is a common
destabilizing p53 mutation and contributes to about 75000
new cancer cases each year.[8b] It results in a cavity at the sur-
face of the protein, which decreases the melting point of the
protein by around 2 8C and contributes to unfolding and ulti-
mately aggregation.[3a] Small molecules that bind to the Y220C
cavity were developed using in silico and in vitro screening,
and the carbazole-based molecule PhiKan083 (Scheme 1c) was
identified to raise the melting temperature (Tm) and slow the
rate of thermal denaturation of p53-Y220C.[19] More recently,
derivatives of halogenated phenols have been reported by
Boeckler and co-workers as a class of molecules that bind to
the p53-Y220C cavity (Scheme 1d).[8b] It is hypothesized that
halogen-bonding interactions with amino acids inside the
cavity plays an important role in binding. The halogenated
compounds modestly increase the melting temperature of a
p53-Y220C model protein and slow the rate of thermally in-
duced protein unfolding/aggregation.[8b] These results demon-
strate that an iodinated-phenol core can be a starting point for
envisioning new molecular designs. In addition to protein un-
folding, p53 Y220C is prone to the loss of Zn2+ in the DNA-
binding domain,[12,13,20] presenting a new opportunity for drug
design.
Multifunctional drugs, namely agents with more than one
therapeutic mechanism, have gained increasing acceptance in
recent years.[21] Multifunctional drugs offer potential advantag-
es over their monofunctional counterparts, namely the poten-
tial to produce additive or synergistic effects by acting on mul-
tiple targets or designing one component to enhance drugga-
ble characteristics of the therapeutic molecule such as blood–
brain-barrier penetration or tissue specificity.[22] Such character-
istics have been successful at enhancing drug efficacy and low-
ering toxic side effects, providing a new avenue in drug dis-
covery from a “one-drug-one-target” to a “one-drug-multiple-
target” strategy.[21d,23] Herein, we report a new series of bifunc-
tional ligands designed to restore wild-type activity in p53-
Y220C by serving as structural stabilizers and as Zn-chaper-
ones. Our new series of compounds feature different binding
groups that tune Zn2+ affinities and promote interactions with
p53-Y220C.
Results and Discussion
Ligand design and synthesis
A series of ligands (L1-L5) that are designed to restore wild-
type function in p53-Y220C were synthesized and character-
ized (Scheme 2). The ligand series was designed with two
motifs in mind: (1) a p53-Y220C binding diiodophenol core,[8b]
and (2) Zn-binding groups to promote metallochaperone acti-
vity.[8c, 16, 24] Metal-binding groups were installed at the 2-posi-
tion, following rationales for related p53-binding molecules.[8b]
Complexes of L1 with a number of different metal ions have
been investigated for their anti-cancer activity, however, the
neutral metal complexes have low aqueous solubility.[25] The
carboxylic acid (L2) and polyethylene glycol (L3) groups were
added to promote water solubility and biological compatibility,
respectively. L4 and L5 include additional metal-binding
groups to promote 1:1 Zn2+ to ligand complex formation.
Molecular docking
To investigate the potential binding mode of L1–L5 with the
mutation-induced cavity in p53-Y220C we employed molecular
docking of the ligands with available X-ray data.[8b] Our model-
ling results predict that the iodinated phenol moiety in L1–L5
orients in the p53-Y220C cavity (Figure 1, S12–14) in a similar
fashion to a known p53-Y220C ligand that incorporates the
same diiodophenol pharmacophore.[8b] In addition, the DPA
metal-binding unit in L4 and L5 does not significantly alter the
interaction, with our lead compound L5 (vide infra) overlap-
Scheme 2. Chemical structure of ligands L1–L5.
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ping with X-ray data (PDBID: 4AGQ) for a known p53-Y220C
binding ligand (Figure S11).
Zinc-binding properties
Previously reported models for Zn-binding in p53 describe two
possible ligation sites, the native binding site (Kd1) and non-
native (Kd2) sites.
[26] The native Zn2+ Kd1 for WTp53 is estimated
to be on the order of 10@12 m.[16,27] This value derives from the
low intracellular levels of free zinc,[16,27] and the fact that under
physiological conditions, WTp53 is predominantly in the holo
(zinc-bound) form.[28] Metallochaperones designed to rescue
zinc-binding in p53 mutants should therefore have Zn2+ affini-
ties that are less than that of the native site (Kd1), yet higher
than that of non-native sites (Kd2), estimated to be about
10@6m for WTp53.[8c] The p53-Y220C mutant is prone to the
loss of Zn2+ due to local unfolding and increased aggregation,
so the exact value of Kd1 is unknown. Assuming that the p53
Y220C mutant should have a slightly weaker Zn affinity than
WTp53, we designed Zn-metallochaperones for p53-Y220C
where the Zn affinity is in between Kd2 and Kd1 (10
@9<Kd chela-
tor<10@12).
Spectrophotometric (UV-visible) pH titrations were carried
out to characterize ligand speciation and Zn-affinity for L1–L5.
These studies show that, at biological pH (7.4), both 1:1 and
2:1 ligand:Zn2+ complexes are present for L1, L2, and L3
(Figure 2).[25] Verani and co- workers proposed that the 1:1
Zn:L1 species is the biologically active form.[25] Our speciation
results are in accord with this observation, predicting that
[ZnL1]+ is the major constituent in solution at pH 7.4. In con-
trast, speciation diagrams of ligands L4 and L5 are described
by a model with only 1:1 ligand to metal species present
(Figure 2). This result is consistent with the presence of an ad-
ditional Zn-binding N-(2-pyridylmethyl) moiety in these li-
gands.[29] Complete data sets, models, and simulations are
given in the Supporting Information.
Analysis of the speciation diagrams for each ligand provides
the Zn2+ affinity of each ligand at physiological pH. The con-
centration of free Zn2+ present in solution at a given pH, re-
ferred to as pm (pZn=@log[Znunchelated]), is a direct estimate of
the metal-ligand affinity when all species in solution are con-
sidered.[30] Calculated values for pZn are reported in Table 1.
The calculated pm values for L1–L3 demonstrate a high Zn2+
-affinity at physiological pH, however, exhibit limited biological
activity (vide infra). The calculated pZn values for the 1:1 com-
plexes L4 and L5 are comparable (7.9 and 8.4 respectively),
and match well with reported Zn-affinities for a ligand series
containing the same metal-binding fragment.[29] These values
afford approximate dissociation constants (Kd) in the low nano-
molar range, an affinity appropriate for functioning as Zn met-
allochaperones for p53-Y220C.
Zn complexes of L4 and L5 were also isolated and character-
ized using 1H NMR, MS, and X-ray crystallography (for ZnL4Cl,
Figure 3), and are in accord with the 1:1 binding of L4 and L5
to Zn2+ modelled above for variable pH titrations. Complete
crystallographic information is in the Supporting Information
(Table S2).
Figure 1. A low energy pose of L5 in the mutation-induced cavity for p53-
Y220C (PDBID: 4AGQ).[8b] The halogen bonding interaction (I····Leu145) is
shown with a yellow line. The hydrogen bond network between the con-
served water, D228, and V147 is shown in red. The Van der Waals surface of
the protein is shown in gray. Atom colors: carbons represented in gray in
the protein and teal for the ligand. Oxygen is shown in red, nitrogen in
blue, and sulfur in yellow. Polar hydrogens are shown in white. Non-polar
hydrogens are omitted for clarity.
Figure 2. (left) Simulated species distribution plot of Zn2++L1. (right) Simu-
lated speciation plot of Zn2++L5. Speciation diagrams made using
HySS2009.
Table 1. Stability constants (logK) of the Zn complexes of L1–L5 and cal-
culated pm values[a] (errors are for the last digit).
pZn[a] Log K
(pH 7.4) ZnL ZnLH ZnLH2 ZnL2
L1 9.2 14.63(1) 6.327(5) – 10.34(5)
L2 10.1 15.439(6) 5.572(4) – 10.65(4)
L3 9.4 13.59(1) 6.427(5) – 10.04(3)
L4 7.9 14.72(1) 7.802(8) – –
L5 8.4 14.63(3) 8.98(2) 2.89(3) –
[a] pZn was calculated using pZn= (@log[Zn2+]free), where Zn2+ is deter-
mined from the Hyss model.[31] [L1–L3]=6.25 mm, [L4–L5]= [Zn2+]=
12.5 mm, 25 8C, I=150 mm NaCl.
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Increasing intracellular levels of Zn2+ in the p53 Y220C cell
line NUGC3
We investigated whether L4 and L5 could serve as Zn-metallo-
chaperones and increase intracellular levels of Zn2+ in the
stomach cancer p53-Y220C cell line NUGC3. NUGC3 cells were
incubated with the fluorescent Zn2+ sensitive probe FZ3-AM
(1 mm),[32] followed by incubation with L4 or L5 (15 mm), 50 mm
ZnCl2, and subsequent imaging. Pyrithione was used as a posi-
tive control for Zn uptake. Both L4 and L5 increased intracellu-
lar levels of Zn2+ in NUGC3 cells, as indicated by increased in-
tracellular fluorescence (Figure 4). However, due to the similar
Zn Kd values of FZ3-AM and L4/L5 (Zn
2+ Kd=15 nm for FZ3-
AM,[32] 13 nm for L4, and 4 nm for L5) Zn-binding to the fluoro-
phore in this experiment is likely restricted, and thus total Zn
Figure 3. ORTEP of ZnL4Cl (50% probability) using POV-Ray, excluding hy-
drogen atoms and solvent. Selected interatomic distances [a]: Zn(1)@N(1-3):
2.093–2.280; Zn(1)@O(1): 1.954; Zn(1)@Cl(1): 2.286.
Figure 4. Treatment of NUGC3 (p53 Y220C) with L4 and L5 increases intracellular Zn2+ . (a) Imaging of intracellular Zn2+ levels in complete serum-free media.
NUGC3 cells were incubated with 1 mm FZ3-AM[24] for 20 minutes at 37 8C, followed by incubation with indicated treatment (ZnCl2=50 mm, L4=L5=15 mm,
50 mm PYR) for 2 hours. 150 mm TPEN was added following incubation with ZnCl2 and L5. Cells were imaged using a Nikon ApoTome microscope and fluores-
cence-quantified using ImageJ. All images were taken at indicated magnification. (B) Fluorescence intensity of FZ3-AM at 488 nm demonstrating relative Zn2+
levels. Blue line indicates mean values, while black error bars demonstrate the 95% confidence interval. * indicates statistical differences from control with
p<0.0001, * indicates statistical differences from control with p<0.01, and D indicates statistical difference from L5+ZnCl2 with p<0.0001. No statistical dif-
ferences are observed between the control and L5+ZnCl2+TPEN.
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uptake is underestimated. L5 increased intracellular Zn2+ levels
more than 4-fold compared to the untreated control, and a
two-fold increase over treatment is observed with L4
(Figure 4). Addition of the strong membrane-permeable Zn-
chelator, N-N-N’-N’-tetrakis-(2-picolyl)-ethylenediamine (TPEN,
Kd=26 fm)
[33] following treatment with L5 results in a signifi-
cant loss of fluorescence, indicating the ability of L5 to deliver
intracellular Zn2+ to stronger Zn chelates. These results dem-
onstrate the ability of L5 and to a lesser extent, L4, to serve as
Zn-metallochaperones in NUGC3 cells containing the p53-
Y220C mutation.
In vitro cytotoxicity assays
L1–L5 and the corresponding zinc complexes of L4 and L5
(ZnL4Cl and ZnL5Cl) were submitted to the National Cancer In-
stitute’s NCI-60 program for in vitro screening against a panel
of 60 human cancer cell lines. After initial 1-dose screening
(10 mm), L1–L3 were rejected from further testing due to their
insufficient cytotoxicity (Table S3). The inactivity of these 2:1
Zn2+-binding ligands could be due to different factors, includ-
ing limited cell uptake of the ligands, and/or limited solubility
of neutral complexes formed from available Zn2+ found in cell
culture media.[33] These ligands were not subjected to further
testing and will not be discussed further. The activity of the 1:1
Zn2+ binding ligands, L4 and L5, was significantly greater and
the aggregate results from their 5-dose testing are displayed in
Table 2. L4 and L5 were found to have a broad range of cyto-
static (GI50, 0.4–2.2 mm) and cytotoxic (LC50, 4.6–93.8 mm) activi-
ty. L5 shows the most promising results, exhibiting high cyto-
static activity in combination with a cytotoxic activity that is
almost three times more potent than that of cisplatin. This
combination of both cytostatic and cytotoxic activity can offer
major advantages in the treatment of cancers.[34]
Interestingly, their corresponding Zn complexes (ZnL4Cl)
and ZnL5Cl) exhibited lower biological activity at the initial
test concentration of 10 mm (Table S3), and did not meet the
necessary threshold for 5-dose testing in the NCI-60 panel.
However, further investigation of the Zn complexes using
stomach cancer cell lines AGS (WTp53) and NUGC3 (p53-
Y220C) showed that their cytotoxicity increases at higher con-
centrations (Figures S37–S40), with ZnL4Cl exhibiting increased
cytotoxicity in comparison to L4 at concentrations >10 mm.
Conversely, L5 is more cytotoxic than ZnL5Cl in both AGS and
NUGC3 cell lines at all concentrations studied.
A heat map of the 5-dose NCI-60 screen for L4 and L5 is
shown in Figure 5, and summarizes the patterns of in vitro cy-
totoxicity (GI50 and LC50) from low activity (blue) to high activi-
ty (red). The most striking result is the level of cytotoxicity dis-
played by L5 across most cell lines. However, L4 and L5 have
little cytotoxic effect on leukemia cell lines (>100 mm in all
cases). Chemoresistance in leukemia cancers are common, es-
pecially in multiple myeloma (RPMI-8226).[36] In contrast, L4
and L5 are highly cytotoxic on the melanoma cell line SK-MEL-
5, with GI50 values 2.6 and 1.5 mm and LC50 values of 13.0 and
5.2 mm, respectively. Note that the NCI-60 panel does not pres-
ently contain p53-Y220C mutant cell lines, though many other
p53 mutants are included. In addition, several highly lethal
cancer types are not represented in the NCI-60 screen (i.e. gas-
tric cancer, pancreatic cancer).
For these two reasons, we further investigated the biological
activity of our compounds in gastric cancer cells. Gastric
cancer is the second leading cause of cancer-related deaths
worldwide, and its lethality is particularly high as indicated by
a 5-year survival rate of around 30%.[37] In addition, there are
gastric cancer cell lines with different p53 status’, including
Table 2. Mean GI50 and LC50 values for L4, L5, and cisplatin from the NCI-
60 screen.
Ligand NSC Number[a] GI50 [mm]
[b] LC50 [mm]
[b]
L4 788646 2.2 70.3
L5 788647 1.5 15.0
Cisplatin 119875 1.5 44.0
[a] NSC number is the compounds internal ID number at the National
Cancer Institute. [b] GI50 values correspond to the dose that inhibits 50%
of cell growth compared to non-treated controls, while LC50 indicates the
concentration required to kill 50% of treated cells.[35]
Figure 5. Heat map showing the in vitro cytotoxicity (left : log10 GI50 ; right:
log10 LC50) of L4 and L5 in the NCI-60 screen. Blue indicates low cytotoxicity
(100 mm) and red indicates high cytotoxicity (0.01 mm).
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p53- Y220C. We tested the in vitro cytotoxicity of our ligand
series on three human gastric cancer cell lines: AGS, which
contains wild-type p53, MKN1, with the V143A point mutation,
and NUGC3, which has the p53-Y220C mutant. The data are re-
ported in Table 3 as IC50 values. The results are in agreement
with the data obtained at the NCI-60 screen; L1–L3 displayed
minimal cytotoxic activity (Table S3), whereas L4 and L5 were
highly cytotoxic on two stomach cancer cell lines tested, AGS
and NUGC3, showing a significant improvement upon IC50
values of cisplatin and oxaliplatin. The compounds however,
do not display higher in vitro cytotoxicity in NUGC3 p53-Y220C
expressing cells compared to the AGS wild-type p53 cell line
after 24-hours of treatment. MKN1 is insensitive to L4 (IC50
51.6 mm), however, the low IC50 value for L5 (1.2 mm) highlights
its increased cytotoxicity in comparison to the other ligands in
the series.
To further characterize the anticancer potential of our lead
cytotoxic compound L5, we assessed its cytotoxic activity in
non-adherent 3D aggregate cultures of NUGC3 cells. The use
of 3D cell cultures is becoming increasingly important in drug
discovery due to their ability to more accurately represent
physiological conditions, including cell signaling processes
(cell- to cell and cell-extracellular matrix involved in cell prolif-
eration).[39] Therefore, the use of 3D cell cultures can better
predict lead compounds for in vivo testing before entering
clinical trials.[40] 3D spheroids of NUGC3 cells were treated with
IC75 concentrations obtained from 2D cultures of L5, and com-
pared to treatment with oxaliplatin, one of the leading drugs
for gastric cancer treatment.[41] Even at the markedly lower
dose of L5 administered compared to oxaliplatin (19.5 mm vs.
250 mm at IC75), L5 remained more cytotoxic (Figure 6).
Apoptotic effects of L4 and L5 in human gastric cancer cell
lines
To investigate the molecular bases for the cytotoxicity of com-
pounds L4 and L5, and probe whether this mechanism is p53-
dependent, we examined whether L4 and L5 could cleave cas-
pase-3, an indicator of apoptosis,[42] in both AGS and NUGC3
cell lines. We also analyzed the levels of p53 expression in the
cells. AGS and NUGC3 cells were treated with the indicated
compounds at both IC50 and IC75 concentrations for 48 hours,
and then cleavage of caspase-3 and p53 protein levels were as-
sessed by Western blot. As expected, oxaliplatin induces an in-
crease in p53 protein levels and low levels of cleaved caspase-
3 in AGS cells are present (Figure 7).[43] Treatment with L5 re-
sults in the presence of low caspase-3 levels comparable to ox-
aliplatin, again highlighting its increased cytotoxicity compared
to L4, which does not induce any changes in either caspase-3
cleavage or p53 expression levels. In contrast to oxaliplatin,
however, the increase in cleaved caspase for L5 is not coupled
with an induction of p53 protein level in the AGS (WTp53) cell
line. In the NUGC3 cell line, oxaliplatin induces an increase in
cleaved caspase-3 at both IC50 and IC75 concentrations. In addi-
tion, oligomeric forms of p53 are observed with molecular
weights corresponding to dimers upon treatment with IC75
concentrations of oxaliplatin, which could indicate p53 activa-
tion.[44] Interestingly, the level of cleaved caspase-3 upon treat-
Figure 6. NUGC3 cells (300 cells/well ; 96 wells/plate) were grown for 4 days
and then treated for 3 days at IC50 and IC75 concentrations as indicated. 3D
cultures were observed by microscopy to estimate clone size (left) and cell
survival was assayed using rezasurin (right). * indicates statistical differences
from non-treated control with p<0.001 as established by ANOVA followed
by Tukey test.
Figure 7. AGS cells (a) and NUGC3 cells (b) were treated for 48 hours with
the IC50 and IC75 concentrations of indicated compound. Proteins were ex-
tracted, and 20 mg were separated on SDS PAGE. Cleaved caspase-3 (Caspase
3*), p53, and actin were then detected by Western blot analysis.
Table 3. In vitro cytotoxicity (IC50 values)
[a] data for stomach cancer cell
lines AGS, MKN1, and NUGC3.
Ligand AGS (WTp53) MKN1 (p53V143A) NUGC3 (p53Y220C)
L4 2.7:0.2 51.6:3.6 2.7:0.1
L5 1.6:0.06 1.2:0.05 1.7:0.02
Cisplatin 25.0:2.4 4.3:0.35 20.0:1.7
Oxaliplatin 7.4:0.9 6.9:0.06 50.0:2.7
[a] IC50 is the concentration needed for 50% reduction of survival based
on survival curves.[38]
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ment with L5 at concentrations as low as 19.5 mm (IC75 concen-
tration) is notably increased in NUGC3 (p53-Y220C) cells in
comparison to AGS (WTp53) cells under the same conditions.
This suggests that the apoptotic effect of L5 is potentiated in
the Y220C mutant cell line (vide infra).
To further explore the mechanism by which L5 imparts bio-
logical activity of p53-Y220C, we investigated whether L5
could bind directly to the p53-Y220C mutant protein using sur-
face plasmon resonance (SPR) (Figure S41a). Unfortunately,
binding at low micromolar concentrations was not observed,
and limited solubility of L5 beyond 400 mm prevents detection
of higher micromolar affinity binding (Figure S41B), a range
relevant to a compound with the same 3,5-diiodophenol phar-
macophore (Kd=225 mm by ITC and 184:23 mm by NMR).[8b]
Immunoprecipitation experiments using the conformation-spe-
cific antibody Pab 240 (recognizing unfolded p53), however,
showed that treatment with L5 reduced the levels of unfolded
p53, indicating that compound treatment leads to a change in
conformation of mutant p53 protein (Figure S42).
Upregulation of p53 transcriptional targets
Based on the high in vitro cytotoxicity of L5 and its increased
activity in p53-Y220C expressing cells in the cleaved caspase
assay mentioned above, we further investigated the role of
p53 in the biological activity of this lead compound. We mea-
sured the expression level of p53 and several p53 target genes
that are involved in either cell cycle arrest (p21)[3a] or apoptosis
(NOXA, PUMA)[3a,7b] in p53-Y220C expressing and p53-silenced
NUGC3 cells. p53 expression was silenced using siRNA
(Figure 8). NUGC3 cells were treated for 24 hours at the IC50
concentration and the expression level of p53 target genes
were measured by RT-PCR. Upon transfection of sip53, expres-
sion levels for NOXA and p21 increase under non-treated (NT)
controls compared to NT under siCT conditions. This is likely
because mutant p53 can bind and inactivate p63 and p73 pro-
teins,[45] both of which also induce cell cycle arrest and apopto-
sis by regulating p53 target genes such as NOXA and p21.[46]
Therefore, removing mutant p53 with sip53 restores function
in p63 and p73, causing their expression levels to increase. In
the presence of p53-Y220C (siCT), expression levels of all three
target genes was significantly higher when treated with L5
compared to non-treated controls (NT), and are of similar
levels induced by oxaliplatin, despite the lower concentration
of L5 (IC50 L5=1.7 mm vs. 50 mm for oxaliplatin) administered
(Figure 8). The increase in genes PUMA and NOXA are indica-
tive of an activation in apoptosis by L5, which correlates to the
results obtained in Figure 7. Upon treatment with sip53, ex-
pression levels of PUMA and NOXA decrease in the case of L5,
however, increase when treated with oxaliplatin. This is likely a
result of the ability of oxaliplatin to induce apoptosis via
PUMA in a p53-independent manner.[47]
Strikingly, treatment of NUGC3 cells with IC50 values of L5 re-
sulted in a 4-fold increase in p21 expression compared to the
non-treated control. These results are obtained without in-
creasing p53 expression levels, unlike oxaliplatin, suggesting
the restoration of wild-type function in existing p53-Y220C.
Furthermore, the diminished expression of p53-Y220C upon
treatment with siRNA significantly reduced the impact of L5
on the mRNA level of the p53 target genes. These results indi-
cate restoration of transcriptional activity to the p53-Y220C
mutant, and that at least part of the biological activity of L5 is
due to restoration of wild-type p53 function.
Summary
The pharmacological reactivation of p53 is a key target in
cancer research, and there is significant promise in the devel-
opment of small molecules to restore wild-type function to
specific p53 mutants. In this work we have designed a series of
multifunctional molecules to reactivate the common p53-
Y220C mutant. We show that compounds L4 and L5 exhibit
Zn metallochaperone activity in the Y220C mutant NUGC3 cell
line. Characterization of their in vitro cytotoxicity in the NCI-60
screen and on stomach cancer cell lines AGS, MKN1, and
NUGC3 identified lead compound L5, which displayed in-
creased cytotoxicity compared to cisplatin and oxaliplatin. Ad-
Figure 8. NUGC3 cells were transfected with control siRNA (siCT) or siRNA di-
rected against p53 (sip53) and then treated for 24 hours with IC50 concentra-
tions of indicated compounds. Top: Proteins were extracted, and 20 mg were
separated on SDS PAGE. p53 and actin were then detected by Western blot-
ting. Bottom: Total RNAs were extracted and RT-qPCR performed to measure
the expression of p53, p21, PUMA, and NOXA. Bars represent means of tripli-
cates with error bars. * indicates statistical differences from NT (siCT) with
p<0.001, D indicates statistical differences from NT (siCT) with p<0.01, C in-
dicates statistical differences from L5 (siCT) with p<0.001.
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ditionally, L5 remained cytotoxic on 3D cell cultures, an impor-
tant characteristic as these systems more directly mimic phys-
iological conditions. Further investigation into the mechanism
of action shows that L5 induces apoptosis in the NUGC3 cell
line via caspase-3, but not in AGS cells under the same condi-
tions. This cytotoxicity is achieved at 19.5 mm, a value 10-fold
larger for oxaliplatin (250 mm, IC75). Similar reports for Y220C-
dependent induction of apoptosis using small molecules have
been reported at higher concentrations, albeit on shorter time
scales.[8b,48] L5 also restores p53 transcriptional activity in the
p53-Y220C mutant NUGC3 cell line. Upregulation of p53 target
genes PUMA, NOXA, and p21 is observed, an effect that is de-
creased upon knockdown of p53. These results are obtained in
the absence of increased p53 expression, suggesting restora-
tion of wild-type function.[45c] Remarkably, our results for L5 are
obtained at low doses of 1.7 mm (L5 IC50), demonstrating the
potent activity of this scaffold.[48a,49] Although binding to re-
combinant p53-Y220C was not observed at such low concen-
trations via SPR, further structural modifications can be made
to increase protein affinity and ensure further target selectivity.
Given the high level of in vitro cytotoxicity of L5 on both
p53-Y220C and WTp53 cell lines, it likely that the activity of L5
is due to both p53-dependent and p53-independent pathways.
Indeed, recent studies on p53 activating scaffolds show that in-
creased ROS generation is an important component of the ob-
served cytotoxicity, in addition to p53 activation.[8c, 49] In the
case of metal-binding agents, ROS-associated toxicity could be
due to the in situ formation of redox-active Cu complexes.[8c, 18a]
We plan to investigate cellular levels of ROS species upon L5
treatment both in wild-type and p53-Y220C cell lines moving
forward. Overall, our novel series of bifunctional scaffolds have
the potential to restore wild-type function in the p53-Y220C
mutant and L5 is a promising scaffold for future structure–ac-
tivity relationship studies to increase affinity for p53-Y220C
and improve selectivity. In combination with major technologi-
cal advancements in gene sequencing capability and a shift to-
wards personalized medicine, the development of small mole-
cules capable of mutant-specific p53 reactivation holds signifi-
cant promise.
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